Isis Pharmaceuticals (ISIS): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Isis Pharmaceuticals ( ISIS) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.1%. By the end of trading, Isis Pharmaceuticals rose $2.42 (6.7%) to $38.48 on heavy volume. Throughout the day, 4,111,752 shares of Isis Pharmaceuticals exchanged hands as compared to its average daily volume of 1,641,400 shares. The stock ranged in a price between $37.12-$39.83 after having opened the day at $37.27 as compared to the previous trading day's close of $36.06. Other companies within the Health Care sector that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 64.3%, Genvec ( GNVC), up 35.4%, ERBA Diagnostics ( ERB), up 33.9% and Omeros Corporation ( OMER), up 28.2%.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Isis Pharmaceuticals has a market cap of $4.2 billion and is part of the drugs industry. Shares are up 247.4% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Isis Pharmaceuticals a buy, 2 analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Isis Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive.

On the negative front, Abiomed ( ABMD), down 11.7%, Electromed ( ELMD), down 11.4%, Cyclacel Pharmaceuticals ( CYCC), down 10.9% and Baxano Surgical ( BAXS), down 10.6% , were all laggards within the health care sector with Biogen Idec ( BIIB) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade